HER2‐positive grade 1 invasive carcinomas of the breast

IF 3.9 2区 医学 Q2 CELL BIOLOGY
Histopathology Pub Date : 2024-09-11 DOI:10.1111/his.15315
Andrew H S Lee, Zsolt Hodi, Areeg Abbas, Ian O Ellis, Emad A Rakha
{"title":"HER2‐positive grade 1 invasive carcinomas of the breast","authors":"Andrew H S Lee, Zsolt Hodi, Areeg Abbas, Ian O Ellis, Emad A Rakha","doi":"10.1111/his.15315","DOIUrl":null,"url":null,"abstract":"AimsThe American Society of Clinical Oncology and College of American Pathologists HER2‐guidelines recommend repeat testing for most grade 1 mammary carcinomas that are HER2‐positive in the core biopsy. This study aimed to assess the value of repeat HER2‐testing and the histological features of HER2‐positive grade 1 carcinomas.Methods and resultsA case‐series of HER2‐results of grade 1 carcinomas was conducted of patients with no pre‐operative systemic treatment over a 5‐year period. HER2‐positive carcinomas had histological review. Twelve HER2‐positive carcinomas were initially reported as grade 1. On review, two were reclassified as grade 2. The remaining 10 carcinomas represented 2% of the 508 grade 1 carcinomas. Eight HER2‐positive grade 1 carcinomas from other years were also studied. HER2‐positive carcinomas more often had marked nuclear pleomorphism (50 versus 6%) and were more often oestrogen receptor‐negative (17 versus 0.8%) and progesterone receptor‐negative (28 versus 8%) compared with HER2‐negative grade 1 carcinomas. Six carcinomas that were HER2 3+ in the core biopsy were also 3+ on repeat assessment. Five of seven carcinomas that were 2+ amplified in the core biopsy were also HER2‐positive in the excision.ConclusionsHER2‐positive grade 1 carcinomas are uncommon, and more often have marked nuclear pleomorphism and lack oestrogen receptor and progesterone receptor expression compared with HER2‐negative grade 1 carcinomas. A HER2‐poitive result in the core biopsy was confirmed in 11 of 13 tumours that had repeat testing.","PeriodicalId":13219,"journal":{"name":"Histopathology","volume":"9 1","pages":""},"PeriodicalIF":3.9000,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Histopathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/his.15315","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

AimsThe American Society of Clinical Oncology and College of American Pathologists HER2‐guidelines recommend repeat testing for most grade 1 mammary carcinomas that are HER2‐positive in the core biopsy. This study aimed to assess the value of repeat HER2‐testing and the histological features of HER2‐positive grade 1 carcinomas.Methods and resultsA case‐series of HER2‐results of grade 1 carcinomas was conducted of patients with no pre‐operative systemic treatment over a 5‐year period. HER2‐positive carcinomas had histological review. Twelve HER2‐positive carcinomas were initially reported as grade 1. On review, two were reclassified as grade 2. The remaining 10 carcinomas represented 2% of the 508 grade 1 carcinomas. Eight HER2‐positive grade 1 carcinomas from other years were also studied. HER2‐positive carcinomas more often had marked nuclear pleomorphism (50 versus 6%) and were more often oestrogen receptor‐negative (17 versus 0.8%) and progesterone receptor‐negative (28 versus 8%) compared with HER2‐negative grade 1 carcinomas. Six carcinomas that were HER2 3+ in the core biopsy were also 3+ on repeat assessment. Five of seven carcinomas that were 2+ amplified in the core biopsy were also HER2‐positive in the excision.ConclusionsHER2‐positive grade 1 carcinomas are uncommon, and more often have marked nuclear pleomorphism and lack oestrogen receptor and progesterone receptor expression compared with HER2‐negative grade 1 carcinomas. A HER2‐poitive result in the core biopsy was confirmed in 11 of 13 tumours that had repeat testing.
HER2 阳性 1 级乳腺浸润癌
目的美国临床肿瘤学会和美国病理学家学会 HER2-指南建议对大多数核心活检呈 HER2 阳性的 1 级乳腺癌进行重复检测。本研究旨在评估重复 HER2 检测的价值以及 HER2 阳性 1 级癌的组织学特征。方法和结果对 5 年内术前未接受系统治疗的 1 级癌患者进行了 HER2 结果病例系列研究。对 HER2 阳性癌进行了组织学检查。12 例 HER2 阳性癌最初被报告为 1 级。经复查,其中两例被重新划分为 2 级。其余 10 例癌占 508 例 1 级癌的 2%。此外,还对其他年份的 8 例 HER2 阳性 1 级癌进行了研究。与HER2阴性1级癌相比,HER2阳性癌更常见于明显的核多形(50对6%),更常见于雌激素受体阴性(17对0.8%)和孕激素受体阴性(28对8%)。在核心活检中HER2为3+的6个癌瘤在再次评估时也是3+。结论HER2阳性的1级癌并不常见,与HER2阴性的1级癌相比,它们通常具有明显的核多形性,缺乏雌激素受体和孕激素受体表达。在重复检测的13个肿瘤中,有11个肿瘤的核心活检结果证实HER2阳性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Histopathology
Histopathology 医学-病理学
CiteScore
10.20
自引率
4.70%
发文量
239
审稿时长
1 months
期刊介绍: Histopathology is an international journal intended to be of practical value to surgical and diagnostic histopathologists, and to investigators of human disease who employ histopathological methods. Our primary purpose is to publish advances in pathology, in particular those applicable to clinical practice and contributing to the better understanding of human disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信